These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question. van Kuilenburg AB Cancer Invest; 2006 Mar; 24(2):215-7. PubMed ID: 16537192 [TBL] [Abstract][Full Text] [Related]
3. Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy. Lee A; Ezzeldin H; Fourie J; Diasio R Clin Adv Hematol Oncol; 2004 Aug; 2(8):527-32. PubMed ID: 16163233 [TBL] [Abstract][Full Text] [Related]
4. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Boisdron-Celle M; Remaud G; Traore S; Poirier AL; Gamelin L; Morel A; Gamelin E Cancer Lett; 2007 May; 249(2):271-82. PubMed ID: 17064846 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction. Bocci G; Di Paolo A; Barbara C; Masi G; Fornaro L; Loupakis F; Allegrini G; Falcone A; Del Tacca M; Danesi R Br J Clin Pharmacol; 2009 Jan; 67(1):132-4. PubMed ID: 19006547 [No Abstract] [Full Text] [Related]
6. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer]. Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867 [TBL] [Abstract][Full Text] [Related]
7. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056 [TBL] [Abstract][Full Text] [Related]
8. [Pro or con the phenotyping/genotyping of patients treated by 5-Fluorouracil to prevent adverse drug reactions?]. Coriat R; Chaussade S Therapie; 2007; 62(2):105-9. PubMed ID: 17582310 [TBL] [Abstract][Full Text] [Related]
9. [Dihydropyrimidine deshydrogenase (DPD): rhythm and consequences]. Barrat-Petit MA; Naulin-Ifi C; Mahler P; Milano G Pathol Biol (Paris); 2005 Jun; 53(5):261-4. PubMed ID: 15939134 [TBL] [Abstract][Full Text] [Related]
11. Quantitative analysis of fluorouracil-related genes in chronic viral hepatitis using microdissection. Kakinuma D; Yoshida H; Mamada Y; Taniai N; Mizuguchi Y; Takahashi T; Shimizu T; Ishikawa Y; Akimaru K; Naito Z; Tajiri T Hepatogastroenterology; 2008; 55(84):826-30. PubMed ID: 18705276 [TBL] [Abstract][Full Text] [Related]
12. Pyrimidine degradation defects and severe 5-fluorouracil toxicity. van Kuilenburg AB; Meinsma R; van Gennip AH Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1371-5. PubMed ID: 15571261 [TBL] [Abstract][Full Text] [Related]
13. No circadian variation of dihydropyrimidine dehydrogenase, uridine phosphorylase, beta-alanine, and 5-fluorouracil during continuous infusion of 5-fluorouracil. Van Kuilenburg AB; Poorter RL; Peters GJ; Van Gennip AH; Van Lenthe H; Stroomer AE; Smid K; Noordhuis P; Bakker PJ; Veenhof CH Adv Exp Med Biol; 1998; 431():811-6. PubMed ID: 9598176 [No Abstract] [Full Text] [Related]
14. Influence of liver dysfunction on dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Nakada T; Yamauchi M; Toda G Gan To Kagaku Ryoho; 2002 Feb; 29 Suppl 1():230-5. PubMed ID: 11890111 [No Abstract] [Full Text] [Related]
15. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Johnson MR; Diasio RB Adv Enzyme Regul; 2001; 41():151-7. PubMed ID: 11384742 [No Abstract] [Full Text] [Related]
16. Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin. van Kuilenburg AB; Klumpen HJ; Westermann AM; Zoetekouw L; Van Lenthe H; Bakker PJ; Richel DJ; Guchelaar HJ Eur J Cancer; 2007 Jan; 43(2):459-65. PubMed ID: 17097873 [TBL] [Abstract][Full Text] [Related]
17. Severe 5-fluorouracil toxicity caused by reduced dihydropyrimidine dehydrogenase activity due to heterozygosity for a G-->A point mutation. van Kuilenburg AB; Vreken P; Beex LV; De Abreu RA; van Gennip AH J Inherit Metab Dis; 1998 Jun; 21(3):280-4. PubMed ID: 9686375 [No Abstract] [Full Text] [Related]
18. [Pharmacogenetics in oncology: 5-fluorouracil and the dihydropyrimidine dehydrogenase]. Lazar A; Jetter A Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1501-4. PubMed ID: 18597209 [TBL] [Abstract][Full Text] [Related]
19. [A case of recurrent gastric cancer with dihydropyrimidine dehydrogenase (DPD) deficiency]. Hashimoto T; Arai K; Iwasaki Y; Saze Z; Takahashi K; Yamaguchi T; Matsumoto H; Yasutome M; Hiruma K; Yamashita Y Gan To Kagaku Ryoho; 2006 Jul; 33(7):985-8. PubMed ID: 16835493 [TBL] [Abstract][Full Text] [Related]
20. Dihydropyrimidine dehydrogenase deficiency in an Indian population. Saif MW; Mattison L; Carollo T; Ezzeldin H; Diasio RB Cancer Chemother Pharmacol; 2006 Sep; 58(3):396-401. PubMed ID: 16421754 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]